Kaplan–Meier survival analyses showed that the median survival times of lower-grade glioma patients, GBM patients, or total glioma patients with higher HOXB5 expression were shorter than those for patients with lower HOXB5 expression (Fig. 2e-g). The gene discussed is HOXB5; the disease is central nervous system cancer.